Public Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings

摘要: Aims: Pharmacogenetic (PGx) tests are intended to improve therapeutic outcomes through predicting a patient's likelihood respond or experience an adverse effect from specific treatment. In addition, PGx testing may also generate ancillary, incidental, disease information unrelated the purpose for which test was ordered. To assess public attitudes toward testing, ancillary risk and related clinical issues, we conducted series of focus groups. Results: Forty-five individuals recruited Durham, NC, participated in four Overall, participants were enthusiastic about though expressed concerns privacy, confidentiality, psychological harms associated with information. Focus group believed that physicians had responsibility disclose information, but concerned managing coping unexpected Conclusion: We find welcomed integra...